Unichem Laboratories Limited (IN:UNICHEMLAB)
:UNICHEMLAB
Want to see IN:UNICHEMLAB full AI Analyst Report?
UNICHEMLAB Stock Chart & Stats
₹443.05
-₹12.85(-1.76%)
At close: 4:00 PM EST
₹443.05
-₹12.85(-1.76%)
Day’s Range― - ―
52-Week Range₹280.00 - ₹656.85
Previous CloseN/A
Volume14.19K
Average Volume (3M)1.03K
Market Cap
₹31.41B
Enterprise Value₹26.65B
Total Cash (Recent Filing)₹1.94B
Total Debt (Recent Filing)₹5.02B
Price to Earnings (P/E)12.5
Beta1.38
Next Earnings
Aug 12, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)12.56
Shares Outstanding70,405,754
10 Day Avg. Volume1,013
30 Day Avg. Volume1,033
Financial Highlights & Ratios
PEG Ratio0.10
Price to Book (P/B)0.76
Price to Sales (P/S)0.94
P/FCF Ratio-14.89
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Balance Sheet StrengthLow, stable leverage and rising equity provide resilience across business cycles, giving Unichem capacity to fund working capital, absorb shocks, or support strategic investments without immediate reliance on volatile cash flow. This structural strength underpins longer-term solvency and strategic optionality.
Diversified Branded Portfolio & MarketsA multi-therapy branded formulation franchise across domestic and export markets reduces single-product and single-market concentration risk. This structural diversification supports stable revenue pools, cross-market commercialization, and the ability to reallocate commercial effort if demand shifts, enhancing medium-term revenue resilience.
Return To ProfitabilityThe company’s recovery from recent loss years to positive net margins indicates tangible operational or commercial improvements. If sustained, this shift can translate into normalized earnings power and a foundation for rebuilding cash generation, improving credit metrics and supporting reinvestment or shareholder returns over the coming months.
Bears Say
Weak Cash GenerationPersistent negative operating cash flow and consistently negative free cash flow mean reported earnings are not converting into cash. This structural cash shortfall forces reliance on external financing or asset sales, raises execution risk if funding tightens, and limits genuine capacity for capex or dividends over the medium term.
Thin Operating MarginsA low operating margin leaves the business exposed to input cost inflation, pricing pressure, or reimbursement changes. Coupled with volatile gross margins, this structural vulnerability reduces earnings predictability and increases the likelihood that modest adverse moves will erode profitability and impede sustained cash flow improvement.
Revenue Growth DecelerationA reversal from multi-year growth to a revenue contraction signals emerging demand, competitive, or execution pressures. If the slowdown persists, it could reverse the recent profit recovery and exacerbate cash burn, increasing the company's dependence on its balance sheet strength or external funding over the medium term.
Unichem Laboratories Limited News
UNICHEMLAB FAQ
What was Unichem Laboratories Limited’s price range in the past 12 months?
Unichem Laboratories Limited lowest stock price was ₹280.00 and its highest was ₹656.85 in the past 12 months.
What is Unichem Laboratories Limited’s market cap?
Unichem Laboratories Limited’s market cap is ₹31.41B.
When is Unichem Laboratories Limited’s upcoming earnings report date?
Unichem Laboratories Limited’s upcoming earnings report date is Aug 12, 2026 which is in 59 days.
How were Unichem Laboratories Limited’s earnings last quarter?
Unichem Laboratories Limited released its earnings results on May 22, 2026. The company reported ₹1.55 earnings per share for the quarter, beating the consensus estimate of N/A by ₹1.55.
Is Unichem Laboratories Limited overvalued?
According to Wall Street analysts Unichem Laboratories Limited’s price is currently Overvalued.
Does Unichem Laboratories Limited pay dividends?
Unichem Laboratories Limited pays a Annually dividend of ₹4 which represents an annual dividend yield of N/A. See more information on Unichem Laboratories Limited dividends here
What is Unichem Laboratories Limited’s EPS estimate?
Unichem Laboratories Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Unichem Laboratories Limited have?
Unichem Laboratories Limited has 70,405,754 shares outstanding.
What happened to Unichem Laboratories Limited’s price movement after its last earnings report?
Unichem Laboratories Limited reported an EPS of ₹1.55 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 0.799%.
Which hedge fund is a major shareholder of Unichem Laboratories Limited?
Currently, no hedge funds are holding shares in IN:UNICHEMLAB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Unichem Laboratories Limited
Unichem Laboratories Limited is an international pharmaceutical company engaged in the development, manufacturing, and commercialization of a wide array of medicinal products. The firm's portfolio features finished pharmaceutical formulations designed to treat numerous health conditions, including those related to gastroenterology, cardiovascular health, diabetes, mental health, neurological disorders, bacterial and other infectious diseases, and pain relief. Beyond these formulations, Unichem also provides active pharmaceutical ingredients (APIs) and offers contract manufacturing solutions. This enterprise was established in 1944 and operates from its corporate headquarters in Mumbai, India.
Technical Analysis
Gufic Biosciences Limited
―
Hikal Limited
―
Indoco Remedies Limited
―
Morepen Laboratories Limited
―
Windlas Biotech Ltd.
―